Department of Zoology, College of Science, King Saud University Riyadh, Saudi Arabia.
Trop Biomed. 2021 Mar 1;38(1):22-27. doi: 10.47665/tb.38.1.004.
This work was carried out to investigate the effect of silymarin combination in the therapeutic plane of schistosomiasis with praziquantel or mirazid to enhance the liver and reduce fibrosis. Mice were divided into 2 main groups, the 1 uninfected group served as control and the 2 group infected subcutaneously with 60 cercaria of S. mansoni per each. The infected group was subdivided into 5 subgroups, the 1 kept untreated, the 2 and 3 treated at the 7 week of infection with (600 mg/kg) of PZQ orally for 3 consecutive days, while the 3 treated also orally with (150 mg/kg) of silymarin daily for 11 weeks. The 4 and 5 groups treated orally at the 7 week of infection with 600 mg/kg of MZ for 3 consecutive days, while the 5 group treated orally also with 150 mg/kg of silymarin daily for 11weeks. IgG determination showed high level in the untreated infected group. Furthermore, the infected groups treated with PZQ and PZQ with silymarin displayed the lower levels than treated with MZ. Additionally, the untreated infected group showed severe pathological changes as hyaline degeneration, inflammation, presence of worm burdens in dilated portal veins, granulomas as well as depositions of collagenous and reticular fibers indicated intense fibrosis. Treatment with PZQ alone resulted in reduction of pathological signs and decreasing of granulomas. Combination with silymarin to PZQ therapy revealed more improvement for liver besides to lowering of granulomas areas and volumes and decreasing of fibrosis. Whereas, treatment with MZ was less effective than PZQ to reduce granulomas areas, volumes and fibrosis. Although, combination of silymarin to MZ treatment resulted in more curative signs and reduction of granulomas areas, volumes and fibrosis. Furthermore, the present study concluded that PZQ still the more effective drug of schistosomiasis treatment than MZ. The silymarin is very useful in schistosomiasis treatment when combined with PZQ or MZ due to its anti-fibrotic effect.
这项工作旨在研究水飞蓟素联合吡喹酮或米氮平在治疗血吸虫病的治疗平面上的作用,以增强肝脏并减少纤维化。将小鼠分为 2 个主要组,1 组未感染作为对照,2 组经皮感染 60 条曼氏血吸虫尾蚴/每只。感染组进一步分为 5 个亚组,1 组未治疗,2 组和 3 组在感染后第 7 周每天口服(600mg/kg)吡喹酮连续 3 天,同时 3 组还每天口服(150mg/kg)水飞蓟素连续 11 周。4 组和 5 组在感染后第 7 周每天口服(600mg/kg)米氮平连续 3 天,而 5 组还每天口服(150mg/kg)水飞蓟素连续 11 周。IgG 测定显示未治疗的感染组水平较高。此外,用吡喹酮和吡喹酮联合水飞蓟素治疗的感染组显示出比用米氮平治疗的感染组水平更低。此外,未治疗的感染组表现出严重的病理变化,如玻璃样变性、炎症、扩张的门静脉中有虫体负担、肉芽肿以及胶原和网状纤维的沉积,表明纤维化严重。单独用吡喹酮治疗可减轻病理体征并减少肉芽肿。联合水飞蓟素与吡喹酮治疗除了降低肉芽肿区域和体积以及减少纤维化外,还对肝脏有更多改善。而米氮平的疗效不如吡喹酮,对降低肉芽肿区域、体积和纤维化的效果较差。然而,与米氮平联合治疗相比,联合水飞蓟素治疗可带来更多的治疗效果,降低肉芽肿区域、体积和纤维化。此外,本研究的结论是,吡喹酮仍然是治疗血吸虫病的更有效药物,优于米氮平。水飞蓟素在联合吡喹酮或米氮平治疗血吸虫病时非常有用,因为它具有抗纤维化作用。